India · Delayed Price · Currency is INR NSE:SUNPHARMA Statistics
Total Valuation
NSE:SUNPHARMA has a market cap or net worth of INR 4.63 trillion. The enterprise value is 4.34 trillion.
| Market Cap | 4.63T |
| Enterprise Value | 4.34T |
Important Dates
The last earnings date was Friday, July 31, 2026.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | Jul 7, 2026 |
Share Statistics
NSE:SUNPHARMA has 2.40 billion shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 2.40B |
| Shares Outstanding | 2.40B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.39% |
| Owned by Insiders (%) | 12.01% |
| Owned by Institutions (%) | 29.11% |
| Float | 1.06B |
Valuation Ratios
The trailing PE ratio is 38.29 and the forward PE ratio is 35.67. NSE:SUNPHARMA's PEG ratio is 2.55.
| PE Ratio | 38.29 |
| Forward PE | 35.67 |
| PS Ratio | 7.73 |
| PB Ratio | 5.52 |
| P/TBV Ratio | 7.69 |
| P/FCF Ratio | 52.56 |
| P/OCF Ratio | 37.29 |
| PEG Ratio | 2.55 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.03, with an EV/FCF ratio of 49.32.
| EV / Earnings | 35.92 |
| EV / Sales | 7.25 |
| EV / EBITDA | 26.03 |
| EV / EBIT | 31.62 |
| EV / FCF | 49.32 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 0.53 |
| Interest Coverage | 37.93 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 19.01% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 4.94% |
| Revenue Per Employee | 12.75M |
| Profits Per Employee | 2.57M |
| Employee Count | 47,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:SUNPHARMA has paid 38.72 billion in taxes.
| Income Tax | 38.72B |
| Effective Tax Rate | 24.22% |
Stock Price Statistics
The stock price has increased by +17.70% in the last 52 weeks. The beta is 0.12, so NSE:SUNPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +17.70% |
| 50-Day Moving Average | 1,901.94 |
| 200-Day Moving Average | 1,786.87 |
| Relative Strength Index (RSI) | 47.09 |
| Average Volume (20 Days) | 2,382,652 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:SUNPHARMA had revenue of INR 599.11 billion and earned 120.96 billion in profits. Earnings per share was 50.40.
| Revenue | 599.11B |
| Gross Profit | 472.83B |
| Operating Income | 137.96B |
| Pretax Income | 159.89B |
| Net Income | 120.96B |
| EBITDA | 165.83B |
| EBIT | 137.96B |
| Earnings Per Share (EPS) | 50.40 |
Balance Sheet
The company has 335.17 billion in cash and 46.27 billion in debt, with a net cash position of 288.89 billion or 120.41 per share.
| Cash & Cash Equivalents | 335.17B |
| Total Debt | 46.27B |
| Net Cash | 288.89B |
| Net Cash Per Share | 120.41 |
| Equity (Book Value) | 838.80B |
| Book Value Per Share | 348.31 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 124.19 billion and capital expenditures -36.09 billion, giving a free cash flow of 88.10 billion.
| Operating Cash Flow | 124.19B |
| Capital Expenditures | -36.09B |
| Depreciation & Amortization | 27.87B |
| Net Borrowing | 17.61B |
| Free Cash Flow | 88.10B |
| FCF Per Share | 36.72 |
Margins
Gross margin is 78.92%, with operating and profit margins of 23.03% and 20.19%.
| Gross Margin | 78.92% |
| Operating Margin | 23.03% |
| Pretax Margin | 26.69% |
| Profit Margin | 20.19% |
| EBITDA Margin | 27.68% |
| EBIT Margin | 23.03% |
| FCF Margin | 15.07% |
Dividends & Yields
This stock pays an annual dividend of 16.00, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | 16.00 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 7 |
| Payout Ratio | n/a |
| Buyback Yield | 0.02% |
| Shareholder Yield | 0.85% |
| Earnings Yield | 2.61% |
| FCF Yield | 1.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:SUNPHARMA is 2,167.21, which is 12.29% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,167.21 |
| Price Target Difference | 12.29% |
| Analyst Consensus | Buy |
| Analyst Count | 34 |
| Revenue Growth Forecast (3Y) | 11.47% |
| EPS Growth Forecast (3Y) | 13.07% |
Stock Splits
The last stock split was on July 29, 2013. It was a forward split with a ratio of 2.
| Last Split Date | Jul 29, 2013 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |